Implementation of a Pharmacist-Driven Vancomycin Area Under the Concentration-Time Curve Monitoring Program Using...

Area of Science:

• Pharmacology and Therapeutics
• Infectious Diseases
• Nephrology

Background:

• Current guidelines recommend 24-hour area under the concentration-time curve (AUC) to minimum inhibitory concentration ratio monitoring for serious methicillin-resistant Staphylococcus aureus infections.
• Limited data exist on the safety, feasibility, and efficacy of vancomycin AUC monitoring in outpatient settings.
• Bayesian software enables single-concentration AUC estimations, unlike traditional methods requiring two concentrations.

Purpose of the Study:

• To evaluate the safety and efficacy of a pharmacist-driven vancomycin AUC monitoring program in outpatients.
• To compare the incidence of nephrotoxicity between vancomycin AUC monitoring and traditional trough-based monitoring.

Main Methods:

• A single-center, quasi-experimental, interrupted time series study was conducted.
• Vancomycin AUC monitoring (goal 400-600 mg·h/L) using Bayesian modeling was implemented in two phases.
• A control group received traditional trough-based vancomycin monitoring.

Main Results:

• Nephrotoxicity incidence was significantly lower in the AUC monitoring group (6.3%) compared to the trough-based group (23.3%; P = .01).
• The AUC group had fewer unusable vancomycin concentrations (0% vs 6%; P < .01).
• No significant differences were observed in 90-day all-cause mortality or readmission rates between the groups.

Conclusions:

• Implementation of a pharmacist-driven vancomycin AUC monitoring program reduced nephrotoxicity in outpatient settings.
• AUC-guided vancomycin therapy is a safe and effective strategy for outpatient management of serious MRSA infections.